Dr. Reddy's Laboratories sells Cloderm® (clocortolone pivalate) Cream, 0.1 % Franchise to EPI Health, LLC
Deepthi | Myequity news | Date : 02-10-2018 14:30:00 IST
Dr. Reddy's Laboratories Limited’s wholly owned subsidiary Promius Pharma, LLC, has sold its rights of Cloderm® (clocortolone pivalate) Cream, 0.1 % and its authorized generic to EPI Health, LLC, an affiliate of EPI Group, LLC.
"We look forward to EPI continuing to support Cloderm, a brand that providers have prescribed for several decades and find as an important treatment option for their patients." says Anil Namboodiripad, Ph.D., Senior Vice President, Proprietary Products, and President, Promius Pharma. About Dr. Reddy's:
Ron Owens, President of EPI Health, said, "We are very pleased to have completed this agreement with Dr. Reddy's to acquire Cloderm® Cream in the United States. Cloderm® Cream, and its authorized generic, is widely recognized and time-tested among the dermatology community. The addition of this product to our growing portfolio will support our ongoing efforts to build a successful prescription branded franchise in the United States while contributing to EPI Health's goal of becoming a leader in medical dermatology."
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.